ReviewRegenerative biomaterials2026
Advanced bone-targeted nanomaterials for the systemic treatment of osteoporosis.
Review in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis.Biogerontology · 2026Review
- Surface-Engineered Phytochemical Nanomedicines for Postmenopausal Osteoporosis: Skeletal Targeting, Imaging-Supported Evaluation, and Therapeutic Performance.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a systemic skeletal disorder marked by reduced bone density and microstructural deterioration, leading to increased fragility and fracture risk. Current clinical treatments, mainly pharmacological, are limited by inadequate efficacy at vertebral sites, unidirectional inhibition of osteoclasts and systemic side effects. Nanotechnology offers a promising strategy to enhance drug delivery and bioavailability. Bone-targeted nanomaterial-based systems employing ligands such as bisphosphonates or peptides enable selective transport to bone tissue. Nanocarriers, including hydroxyapatite-based ones, can actively target osteoblasts or osteoclasts and support sustained release. This review synthesizes cellular-level insights into osteoporosis pathogenesis, critiques current therapeutic limitations and highlights advances in targeted nanomedicines. Specifically, it focuses on bone-targeting polymeric nanoparticle systems, which promote bone repair through multiple mechanisms: targeted drug delivery, modulation of the bone microenvironment, dual regulation of osteoblasts and osteoclasts, stimulation of bioactive signals from internal organs and restoration of mitochondrial homeostasis. By enhancing bone metabolism, these nanotherapeutic strategies present transformative potential for osteoporosis treatment and offer innovative directions for developing advanced regenerative biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.